Titre :
|
mTOR-therapy and targeted treatment opportunities in mTOT-related epilepsies associated with cortical malformations (2023)
|
Auteur(s) :
|
Stéphane AUVIN, Auteur ;
Stéphanie BAULAC, Auteur
|
Type de document :
|
Article
|
Dans :
|
Revue neurologique (Vol. 179 n° 4, avril 2023)
|
Article en page(s) :
|
pp. 337-344.
|
Langue(s) :
|
Anglais
|
Mot-clé :
|
Epilepsie
;
Génétique
;
Médicament
;
Risque génétique
;
Traitement
;
Trouble du neurodéveloppement
|
Résumé :
|
Dysregulation of the mTOR pathway is now well documented in several neurodevelopmental disorders associated with epilepsy. Mutations of mTOR pathway genes are involved in tuberous sclerosis complex (TSC) as well as in a range of cortical malformations from hemimegalencephaly (HME) to type II focal cortical dysplasia (FCD II), leading to the concept of “mTORopathies” (mTOR pathway-related malformations). This suggests that mTOR inhibitors (notably rapamycin (sirolimus), and everolimus) could be used as antiseizure medication. In this review, we provide an overview of pharmacological treatments targeting the mTOR pathway for epilepsy based on lectures from the ILAE French Chapter meeting in October 2022 in Grenoble. There is strong preclinical evidence for the antiseizure effects of mTOR inhibitors in TSC and cortical malformation mouse models. There are also open studies on the antiseizure effects of mTOR inhibitors, as well as one phase III study showing the antiseizure effect of everolimus in TSC patients. Finally, we discuss to which extent mTOR inhibitors might have properties beyond the antiseizure effect on associated neuropsychiatric comorbidities. We also discuss a new way of treatment on the mTOR pathways. [résumé d'éditeur]
|